DrugScreens.com brings back Molly McClure as fractional CMO

DrugScreens.com has appointed Molly McClure as fractional chief marketing officer as the investor-backed drug screening supplier prepares for its next stage of expansion. McClure helped shape the brand before launch and will now lead marketing, growth and customer experience efforts for the national company.

Why it matters: - DrugScreens.com is moving from brand-building mode into a broader growth phase with investor backing and a larger national customer base. - The appointment adds a leader who helped create the company’s original positioning, which could speed execution and keep the brand consistent as the business expands. - Drug screening affects workplace safety, public safety, recovery and organizational risk, so customer trust and clarity matter in this category.

What happened: - DrugScreens.com named Molly McClure as fractional chief marketing officer. - McClure is returning to the company after helping build the brand before launch. - The announcement said the move is part of the company’s next stage of growth. - The company is based in the U.S. and serves organizations nationally.

The details: - McClure worked with the founding team on the brand’s early positioning, messaging, visual identity, website strategy, website build, go-to-market foundation and digital presence. - In the new role, McClure will oversee brand strategy, growth strategy, demand generation, e-commerce, content, SEO, customer acquisition, market expansion and customer experience. - Corbin Smith, investor and advisor to DrugScreens.com, said McClure understood early that the company was building a trusted resource for organizations responsible for workplace safety, treatment, compliance and drug screening programs. - DrugScreens.com said its portfolio continues to expand across urine, oral fluid and other drug screening solutions. - The company serves employers, staffing organizations, treatment and recovery programs, healthcare organizations, government entities and other professional testing environments. - The company offers products from established manufacturers and emphasizes product education, responsive service and a simplified purchasing experience. - McClure has worked with brands in highly regulated industries, where customer trust, compliance and clarity are critical. - McClure said the company’s opportunity is to make drug screening easier to understand and easier to navigate. - The company included a LinkedIn page in its release: DrugScreens.com on LinkedIn.

Between the lines: - Bringing back an original brand builder signals that DrugScreens.com wants continuity between its startup identity and its next growth phase. - The emphasis on storytelling, SEO and customer experience suggests the company is leaning on marketing infrastructure, not just product breadth, to win share. - The focus on regulated industries points to a strategy built around credibility and compliance, not just convenience.

What's next: - McClure is expected to guide the company’s next wave of branding and customer acquisition work. - DrugScreens.com said it is investing in leadership, technology and marketing capabilities to support continued expansion. - The company’s next chapter will focus on where it invests, who it serves and how it differentiates in the market.

The bottom line: - DrugScreens.com is pairing investor support with a familiar marketing leader to scale faster while keeping its brand focused on trust and clarity.